Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aslan Pharmaceuticals Ltd ADR (ASLN)
Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,765
  • Shares Outstanding, K 16,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,380 K
  • 60-Month Beta 1.44
  • Price/Sales 0.91
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ASLN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.24
  • Most Recent Earnings $-0.56 on 10/27/23
  • Latest Earnings Date 03/22/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 436.73% ( +436.73%)
  • Historical Volatility 145.25%
  • IV Percentile 90%
  • IV Rank 36.25%
  • IV High 1,184.11% on 12/18/23
  • IV Low 11.85% on 04/11/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 22
  • Open Int (30-Day) 33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.70
  • Number of Estimates 2
  • High Estimate -0.65
  • Low Estimate -0.75
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +32.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4000 +75.00%
on 02/22/24
0.7100 -1.41%
on 02/28/24
+0.1010 (+16.86%)
since 01/26/24
3-Month
0.3920 +78.57%
on 12/26/23
0.9455 -25.97%
on 01/12/24
+0.0200 (+2.94%)
since 11/28/23
52-Week
0.3920 +78.57%
on 12/26/23
4.6900 -85.07%
on 05/12/23
-3.0750 (-81.46%)
since 02/28/23

Most Recent Stories

More News
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.

ASLN : 0.7000 (+47.40%)
SNY : 48.00 (-0.44%)
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.

ASLN : 0.7000 (+47.40%)
BCEL : 0.2670 (-1.11%)
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?

Here is how Apexigen, Inc. (APGN) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

APGN : 0.3851 (+8.48%)
ASLN : 0.7000 (+47.40%)
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

ASLN : 0.7000 (+47.40%)
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.

ASLN : 0.7000 (+47.40%)
AWH : 3.85 (-4.94%)
DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

ADAP : 1.6100 (-5.85%)
DBVT : 0.8037 (-2.82%)
ASLN : 0.7000 (+47.40%)
IMCR : 69.21 (-1.76%)
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

LLY : 757.64 (-0.96%)
PRQR : 2.00 (-4.53%)
ASLN : 0.7000 (+47.40%)
IMCR : 69.21 (-1.76%)
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

PFE : 27.04 (+0.56%)
ASLN : 0.7000 (+47.40%)
ORIC : 11.75 (-1.92%)
IMCR : 69.21 (-1.76%)
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

MRK : 128.19 (-0.65%)
AMGN : 277.46 (-0.37%)
MRTX : 58.70 (-0.17%)
ASLN : 0.7000 (+47.40%)
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

REGN : 987.61 (-0.58%)
SNY : 48.00 (-0.44%)
ASLN : 0.7000 (+47.40%)
IPHA : 2.64 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003...

See More

Key Turning Points

3rd Resistance Point 1.0099
2nd Resistance Point 0.8599
1st Resistance Point 0.7800
Last Price 0.7000
1st Support Level 0.5501
2nd Support Level 0.4001
3rd Support Level 0.3202

See More

52-Week High 4.6900
Fibonacci 61.8% 3.0482
Fibonacci 50% 2.5410
Fibonacci 38.2% 2.0338
Last Price 0.7000
52-Week Low 0.3920

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar